Tim Anderson
Stock Analyst at B of A Securities
(3.57)
# 2,122
Out of 5,182 analysts
51
Total ratings
55.17%
Success rate
6.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $68 → $67 | $57.78 | +15.96% | 3 | Apr 9, 2026 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $220 → $221 | $225.34 | -1.93% | 10 | Jan 22, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,286 → $1,268 | $868.27 | +46.04% | 2 | Dec 15, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $105 → $120 | $110.23 | +8.86% | 5 | Dec 15, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $543 → $627 | $744.44 | -15.78% | 3 | Oct 29, 2025 | |
| PFE Pfizer | Maintains: Neutral | $28 → $30 | $26.79 | +11.98% | 3 | Oct 3, 2025 | |
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $340.18 | -20.04% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $86.49 | +0.59% | 1 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $5.52 | +352.90% | 3 | Aug 28, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $197.38 | +3.35% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $116 → $126 | $127.75 | -1.37% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $41 → $34 | $48.70 | -30.18% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $180.67 | -1.48% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $144.19 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $187.51 | - | 1 | Sep 22, 2017 |
Bristol-Myers Squibb Company
Apr 9, 2026
Maintains: Buy
Price Target: $68 → $67
Current: $57.78
Upside: +15.96%
Johnson & Johnson
Jan 22, 2026
Maintains: Neutral
Price Target: $220 → $221
Current: $225.34
Upside: -1.93%
Eli Lilly and Company
Dec 15, 2025
Maintains: Buy
Price Target: $1,286 → $1,268
Current: $868.27
Upside: +46.04%
Merck & Co.
Dec 15, 2025
Maintains: Buy
Price Target: $105 → $120
Current: $110.23
Upside: +8.86%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Underperform
Price Target: $543 → $627
Current: $744.44
Upside: -15.78%
Pfizer
Oct 3, 2025
Maintains: Neutral
Price Target: $28 → $30
Current: $26.79
Upside: +11.98%
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $340.18
Upside: -20.04%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $86.49
Upside: +0.59%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $5.52
Upside: +352.90%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $197.38
Upside: +3.35%
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $127.75
Upside: -1.37%
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $48.70
Upside: -30.18%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $180.67
Upside: -1.48%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $144.19
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $187.51
Upside: -